Vanda Pharmaceuticals: H.C. Wainwright Raises Price Target Following FDA Approval for Motion Sickness - Expert Sees 168% Price Potential

Vanda Pharmaceuticals (VNDA) has established itself in the biopharmaceutical industry as a specialist in central nervous system disorders and rare diseases. The company pursues a precise scientific approach to develop therapies for patients whose medical needs have so far been inadequately addressed. The core portfolio focuses on solutions in psychiatry, sleep medicine, and neurology, with the business model aimed at optimizing active ingredients through targeted clinical research and subsequently marketing them independently in the US market....